Publicacions en col·laboració amb investigadors/es de Beckman Research Institute (7)

2024

  1. Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial

    Nature Medicine, Vol. 30, Núm. 1, pp. 271-278

2023

  1. HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 35, pp. 5363-5375

  2. Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation.

    New England Journal of Medicine, Vol. 389, Núm. 8, pp. 710-721

2022

  1. Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials

    JTO Clinical and Research Reports, Vol. 3, Núm. 9

2017

  1. Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: Two-year outcomes from two randomized, open-label, phase III Trials (CheckMate 017 and CheckMate 057)

    Journal of Clinical Oncology, Vol. 35, Núm. 35, pp. 3924-3933

  2. Phase II trial of atezolizumab as first-line or subsequent therapy for patients with programmed death-ligand 1-selected advanced non-small-cell lung cancer (BIRCH)

    Journal of Clinical Oncology

2015

  1. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer

    New England Journal of Medicine, Vol. 373, Núm. 2, pp. 123-135